Table I.
Clinical and Laboratory Features of Patients and Controls
| VT+/PM− (n = 9) | VT−/PM+ (n = 7) | HC (n = 6) | |
|---|---|---|---|
| Age (mean ± SEM) | 53.3 ± 5.9 | 43.4 ± 1.9 | 33.5 ± 3.7 |
| Sex | 6 F/3 M | 7 F | 6 F |
| PAPS | 6 (66.6%) | 6 (85.7%) | 0 |
| SLE | 3 (33.3%) | 1 (14.3%) | 0 |
| No. pregnancies | 4 | 24 | 3 |
| Live births | 4 | 16 | 3 |
| Total APS-related PM | 0 | 7 (6 ST-PL, 1 TT-PL) | 0 |
| Arterial thrombosis | 5 (3 CVA, 2 TIA) | 0 | 0 |
| Venous thrombosis | 5 (4 DVT, 4 PE) | 0 | 0 |
| Plasma LA positive | 8 | 6 | NT |
| Serum aCL (mean GPLU ± SEM) | 144.3 ± 23.4 | 120.9 ± 14.6 | 4.3 ± 0.8 |
| Serum anti-β2GPI (mean SU ± SEM) | 83.3 ± 17.3 | 84.4 ± 28.9 | 0.2 ± 0.1 |
| IgG aCL (mean GPLU ± SEM) | 86.5 ± 19.7 | 65 ± 10.6 | 0 ± 0 |
| IgG anti-β2GPI (mean SU ± SEM) | 61.3 ± 26.3 | 71.8 ± 38 | 0 ± 0 |
aCL, anti-cardiolipin antibodies; anti-β2GPI, anti-β2-glycoprotein I antibodies; CVA, cerebrovascular accident; DVT, deep vein thrombosis; F, female; GPLU, IgG phospholipid units; LA, lupus anticoagulant; M, male; NT, not tested; PAPS, primary antiphospholipid syndrome; PM, pregnancy morbidity; PE, pulmonary embolus; CVA, cerebrovascular accident; SEM, standard error of the mean; SLE, systemic lupus erythematosus; ST-PL, second-trimester pregnancy loss; SU, standard units; TIA, transient ischaemic attack; TT-PL, third-trimester pregnancy loss.
Lupus anticoagulant activity was checked on plasma samples by dilute Russell viper venom time and activated partial thromboplastin time. Purified IgG was tested at the final experimental concentration of 100 μg/mL.